Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.48 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.45 |
| ▸ | SCD | O00767 | 2/20 | 0.45 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.42 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4220273 | 0.89 | NOTUM (0.62) | NOTUMUSP30SCDSCD5FAAH | |
| SCHEMBL4050311 | 0.79 | NOTUM (0.74) | NOTUMFAAHCYP2C9CYP2C19TDP1 | |
| SCHEMBL4041589 | 0.78 | NOTUM (0.51) | NOTUMCHRNB2CHRNA4CLK4TDP1 | |
| SCHEMBL1844414 | 0.78 | NOTUM (0.53) | NOTUMALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL3955619 | 0.78 | NOTUM (0.51) | NOTUMCHRNB2CHRNA4TDP1ALDH1A1 | |
| SCHEMBL4050876 | 0.78 | CYP3A4 (0.38) | NOTUMUSP30SCDSCD5FAAH | |
| Lithium Ion SCHEMBL30047029 | 0.76 | NOTUM (0.70) | NOTUMFAAHCYP2C9CYP2C19TDP1 | |
| SCHEMBL1795060 | 0.76 | CYP3A4 (0.57) | NOTUMSCDSCD5CYP3A4CYP2C9 | |
| SCHEMBL4049004 | 0.75 | TP53 (0.43) | USP30SCDSCD5FAAHCYP3A4 | |
| SCHEMBL5483599 | 0.74 | PTPN1 (0.69) | SCDSCD5FAAHTDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2027128-A2 | FUSED HETEROCYLIC COMPOUNDS AND THEIR USE AS MGLUR5 MODULATORS | Astra Zeneca AB (SE) | 2009-02-25 | — | — | EP | claimed |
| WO-2007130825-A2 | FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS MGLUR5 MODULATORS | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | WO | claimed |
| EP-1305026-B1 | BARBITURIC ACID ANALOGS AS THERAPEUTIC AGENTS | NOVUSPHARMA SPA (IT) | 2009-05-13 | — | — | EP | disclosed |
| EP-2027129-A2 | FUSED HETEROCYLIC COMPOUNDS AND THEIR USE AS MGLUR5 MODULATORS | AstraZeneca AB (SE) | 2009-02-25 | — | — | EP | disclosed |
| US-20080113993-A1 | BARBITURIC ACID ANALOGS AS THERAPEUTIC AGENTS | VIA ARIOSTO, 23 (IT) | 2008-05-15 | — | — | US | disclosed |
| EP-1919901-A1 | SUBSTITUTED PIPERAZINES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007130824-A2 | FUSED HETEROCYLIC COMPOUNDS AND THEIR USE AS MGLUR5 MODULATORS | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007021573-A1 | SUBSTITUTED PIPERAZINES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | WO | disclosed |
| US-20030229108-A1 | Barbituric acid analogs as therapeutic agents | NOVUSPHARMA S.P.A. (IT) | 2003-12-11 | — | — | US | disclosed |
| EP-1305026-A2 | BARBITURIC ACID ANALOGS AS THERAPEUTIC AGENTS | Novuspharma S.p.A. (IT) | 2003-05-02 | — | — | EP | disclosed |
| WO-2001093841-A2 | BARBITURIC ACID ANALOGS AS THERAPEUTIC AGENTS | NOVUSPHARMA S.P.A. (IT) | 2001-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229108-A1 | Barbituric acid analogs as therapeutic agents | HIF1AN, HIF1A, VHL | NOTUM 4249/4885USP30 2540/4885SCD 3452/4885 |
| US-20080113993-A1 | BARBITURIC ACID ANALOGS AS THERAPEUTIC AGENTS | HIF1A, HIF1AN, PDGFA | NOTUM 4670/4885USP30 2112/4885SCD 3850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.